583 
rehabilitation activities, and interventions for il-
licit drug use and dependence; and 
‘‘(M) research related to illicit drug use and 
any of the activities described in this para-
graph.’’; 
(8) by inserting after paragraph (6), as so redes-
ignated, the following: 
‘‘(7) EMERGING
DRUG
THREAT.—The term 
‘emerging drug threat’ means the occurrence of a new 
and growing trend in the use of an illicit drug or 
class of drugs, including rapid expansion in the sup-
ply of or demand for such drug. 
‘‘(8) ILLICIT DRUG USE; ILLICIT DRUGS; ILLEGAL 
DRUGS.—The terms ‘illicit drug use’, ‘illicit drugs’, 
and ‘illegal drugs’ include the illegal or illicit use of 
prescription drugs. 
‘‘(9) LAW
ENFORCEMENT.—The term ‘law en-
forcement’ or ‘drug law enforcement’ means all efforts 
by a Federal, State, local, or Tribal government agen-
cy to enforce the drug laws of the United States or 
any State, including investigation, arrest, prosecu-
tion, and incarceration or other punishments or pen-
alties.’’; 
(9) by amending paragraph (11), as so redesig-
nated, to read as follows:
584 
‘‘(11) NATIONAL DRUG CONTROL PROGRAM AGEN-
CY.—The term ‘National Drug Control Program 
Agency’ means any agency (or bureau, office, inde-
pendent agency, board, division, commission, subdivi-
sion, unit, or other component thereof) that is respon-
sible for implementing any aspect of the National 
Drug Control Strategy, including any agency that re-
ceives Federal funds to implement any aspect of the 
National Drug Control Strategy, but does not include 
any agency that receives funds for drug control activ-
ity solely under the National Intelligence Program or 
the Joint Military Intelligence Program.’’; 
(10) in paragraph (12), as so redesignated— 
(A) by inserting ‘‘or ‘Strategy’ ’’ before 
‘‘means’’; and 
(B) by inserting ‘‘, including any report, 
plan, or strategy required to be incorporated into 
or issued concurrently with such strategy’’ before 
the period at the end; 
(11) by inserting after paragraph (12), as so re-
designated, the following: 
‘‘(13) NONPROFIT
ORGANIZATION.—The term 
‘nonprofit organization’ means an organization that 
is described in section 501(c)(3) of the Internal Rev-
585 
enue Code of 1986 and exempt from tax under section 
501(a) of such Code.’’; 
(12) in paragraph (14), as so redesignated, by 
striking ‘‘Unless the context clearly indicates other-
wise, the’’ and inserting ‘‘The’’; 
(13) by inserting after paragraph (15), as so re-
designated, the following: 
‘‘(16) SUBSTANCE USE DISORDER TREATMENT.— 
The term ‘substance use disorder treatment’ means an 
evidence-based, professionally directed, deliberate, and 
planned regimen including evaluation, observation, 
medical monitoring, and rehabilitative services and 
interventions such as pharmacotherapy, behavioral 
therapy, and individual and group counseling, on an 
inpatient or outpatient basis, to help patients with 
substance use disorder reach recovery.’’; and 
(14) in paragraph (17), as so redesignated— 
(A) by redesignating subparagraphs (B), 
(C), (D), and (E), as subparagraphs (C), (D), 
(E), and (F), respectively; 
(B) by inserting after subparagraph (A) the 
following: 
‘‘(B) domestic law enforcement;’’; 
(C) in subparagraph (E), as so redesig-
nated, by striking ‘‘and’’ at the end;
586 
(D) in subparagraph (F), as so redesig-
nated, by striking the period at the end and in-
serting a semicolon; and 
(E) by adding at the end the following: 
‘‘(G) activities to prevent the diversion of 
drugs for their illicit use; and 
‘‘(H) research related to any of the activi-
ties described in this paragraph.’’. 
SEC. 8217. AMENDMENTS TO ADMINISTRATION OF THE OF-
FICE. 
(a) RESPONSIBILITIES OF OFFICE.—Section 703(a) of 
the Office of National Drug Control Policy Reauthorization 
Act of 1998 (21 U.S.C. 1702(a)) is amended— 
(1) by striking paragraph (1) and inserting the 
following: 
‘‘(1) lead the national drug control effort, includ-
ing coordinating with the National Drug Control 
Program Agencies;’’; 
(2) in paragraph (2), by inserting before the 
semicolon the following: ‘‘, including the National 
Drug Control Strategy’’; 
(3) in paragraph (3), by striking ‘‘and’’ at the 
end; and
587 
(4) by striking paragraph (4) and all that fol-
lows through ‘‘the National Academy of Sciences.’’ 
and inserting the following: 
‘‘(4) evaluate the effectiveness of national drug 
control policy efforts, including the National Drug 
Control Program Agencies’ program, by developing 
and applying specific goals and performance meas-
urements and monitoring the agencies’ program-level 
spending; 
‘‘(5) identify and respond to emerging drug 
threats related to illicit drug use; 
‘‘(6) administer the Drug-Free Communities 
Program, the High-Intensity Drug Trafficking Areas 
Program, and other grant programs directly author-
ized to be administered by the Office in furtherance 
of the National Drug Control Strategy; and 
‘‘(7) facilitate broad-scale information sharing 
and data standardization among Federal, State, and 
local entities to support the national drug control ef-
forts.’’. 
(b) ETHICS GUIDELINES.—Section 703(d) of the Office 
of National Drug Control Policy Reauthorization Act of 
1998 (21 U.S.C. 1702(d)) is amended by adding at the end 
the following:
588 
‘‘(4) ETHICS GUIDELINES.—The Director shall 
establish written guidelines setting forth the criteria 
to be used in determining whether a gift or donation 
should be declined under this subsection because the 
acceptance of the gift or donation would— 
‘‘(A) reflect unfavorably upon the ability of 
the Director or the Office, or any employee of the 
Office, to carry out responsibilities or official du-
ties under this chapter in a fair and objective 
manner; or 
‘‘(B) compromise the integrity or the ap-
pearance of integrity of programs or services 
provided under this chapter or of any official in-
volved in those programs or services. 
‘‘(5) REGISTRY OF GIFTS.—The Director shall 
maintain a list of— 
‘‘(A) the source and amount of each gift or 
donation accepted by the Office; and 
‘‘(B) the source and amount of each gift or 
donation accepted by a contractor to be used in 
its performance of a contract for the Office. 
‘‘(6) REPORT TO CONGRESS.—The Director shall 
include in the annual assessment under section 706(g) 
a copy of the registry maintained under paragraph 
(5).’’.
589 
(c) APPOINTMENT OF DIRECTOR AND DEPUTY DIREC-
TOR.—Section 704(a) of the Office of National Drug Con-
trol Policy Reauthorization Act of 1998 (21 U.S.C. 1703(a)) 
is amended— 
(1) in paragraph (1), by striking subparagraphs 
(A), (B), and (C), and inserting the following: 
‘‘(A) DIRECTOR.— 
‘‘(i) IN GENERAL.—There shall be at 
the head of the Office a Director who shall 
hold the same rank and status as the head 
of an executive department listed in section 
101 of title 5, United States Code. 
‘‘(ii) 
APPOINTMENT.—The 
Director 
shall be appointed by the President, by and 
with the advice and consent of the Senate, 
and shall serve at the pleasure of the Presi-
dent. 
‘‘(B) DEPUTY DIRECTOR.—There shall be a 
Deputy Director who shall report directly to the 
Director, and who shall be appointed by the 
President, and shall serve at the pleasure of the 
President. 
‘‘(C) COORDINATORS.—The following coor-
dinators shall be appointed by the Director:
590 
‘‘(i) Performance Budget Coordinator, 
as described in section 704(c)(4). 
‘‘(ii) Interdiction Coordinator, as de-
scribed in section 711. 
‘‘(iii) 
Emerging 
and 
Continuing 
Threats Coordinator, as described in section 
709. 
‘‘(iv) State, Local, and Tribal Affairs 
Coordinator, to carry out the activities de-
scribed in section 704(j). 
‘‘(v) Demand Reduction Coordinator, 
as described in subparagraph (D). 
‘‘(D) DEMAND REDUCTION COORDINATOR.— 
The Director shall designate or appoint a United 
States Demand Reduction Coordinator to be re-
sponsible for the activities described in section 
702(3). The Director shall determine whether the 
coordinator position is a noncareer appointee in 
the Senior Executive Service or a career ap-
pointee in a position at level 15 of the General 
Schedule (or equivalent).’’; 
(2) in paragraph (5), by striking ‘‘such official’’ 
and inserting ‘‘such officer or employee’’; and 
(3) by adding at the end the following:
591 
‘‘(6) PROHIBITION ON THE USE OF FUNDS FOR 
BALLOT INITIATIVES.—No funds authorized under this 
title may be obligated for the purpose of expressly ad-
vocating the passage or defeat of a State or local bal-
lot initiative.’’. 
(d) CONSULTATION.—Section 704(b) of the Office of 
National Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1703(b)) is amended— 
(1) in paragraph (19), by striking ‘‘; and’’ and 
inserting a semicolon; 
(2) in paragraph (20), by striking the period at 
the end and inserting ‘‘; and’’; and 
(3) by adding at the end the following: 
‘‘(21) in order to formulate the national drug 
control policies, goals, objectives, and priorities— 
‘‘(A) shall consult with and assist— 
‘‘(i) State and local governments; 
‘‘(ii) National Drug Control Program 
Agencies; 
‘‘(iii) each committee, working group, 
council, or other entity established under 
this chapter, as appropriate; 
‘‘(iv) the public; 
‘‘(v) appropriate congressional com-
mittees; and
592 
‘‘(vi) any other person in the discretion 
of the Director; and 
‘‘(B) may— 
‘‘(i) establish advisory councils; 
‘‘(ii) acquire data from agencies; and 
‘‘(iii) request data from any other enti-
ty.’’. 
(e) NATIONAL DRUG CONTROL PROGRAM BUDGET.— 
Section 704(c) of the Office of National Drug Control Policy 
Reauthorization Act of 1998 (21 U.S.C. 1703(c)) is amend-
ed— 
(1) in paragraph (2)— 
(A) in subparagraph (A), by striking 
‘‘paragraph (1)(C);’’ and inserting the following: 
‘‘paragraph (1)(C) and include— 
‘‘(i) the funding level for each National 
Drug Control Program agency; and 
‘‘(ii) alternative funding structures 
that could improve progress on achieving 
the goals fo the National Drug Control 
Strategy; and’’; 
(B) in subparagraph (B), strike ‘‘the Presi-
dent; and’’ and inserting ‘‘the President and 
Congress.’’; and 
(C) by striking subparagraph (C);
593 
(2) in paragraph (3)(E), by striking clause (ii) 
and inserting the following: 
‘‘(ii) CERTIFICATION.—The Director 
shall— 
‘‘(I) review each budget submis-
sion submitted under subparagraph 
(A); 
‘‘(II) based on the review under 
clause (i), make a determination as to 
whether the budget submission of a Na-
tional Drug Control Program agency 
includes the funding levels and initia-
tives described in subparagraph (B); 
and 
‘‘(III) submit to the appropriate 
congressional committees— 
‘‘(aa) a written statement 
that either— 
‘‘(AA) certifies that the 
budget submission includes 
sufficient funding; or 
‘‘(BB) 
decertifies 
the 
budget submission as not in-
cluding sufficient funding;
594 
‘‘(bb) a copy of the descrip-
tion made under subparagraph 
(B); and 
‘‘(cc) the budget recommenda-
tions 
made 
under 
subsection 
(b)(8).’’; and 
(3) by adding at the end the following: 
‘‘(5) PERFORMANCE-BUDGET COORDINATOR.— 
‘‘(A) DESIGNATION.—The Director shall 
designate or appoint a United States Perform-
ance-Budget Coordinator to— 
‘‘(i) ensure the Director has sufficient 
information necessary to analyze the per-
formance of each National Drug Control 
Program Agency, the impact Federal fund-
ing has had on the goals in the Strategy, 
and the likely contributions to the goals of 
the Strategy based on funding levels of each 
National Drug Control Program Agency, to 
make an independent assessment of the 
budget request of each agency under this 
subsection; 
‘‘(ii) advise the Director on agency 
budgets, performance measures and targets, 
and additional data and research needed to
595 
make informed policy decisions under this 
section and section 706; and 
‘‘(iii) other duties as may be deter-
mined by the Director with respect to meas-
uring or assessing performance or agency 
budgets. 
‘‘(B) DETERMINATION
OF
POSITION.—The 
Director shall determine whether the coordinator 
position is a noncareer appointee in the Senior 
Executive Service or a career appointee in a po-
sition at level 15 of the General Schedule (or 
equivalent). 
‘‘(6) BUDGET ESTIMATE OR REQUEST SUBMIS-
SION TO CONGRESS.—Whenever the Director submits 
any budget estimate or request to the President or the 
Office of Management and Budget, the Director shall 
concurrently transmit to the appropriate congres-
sional committees a detailed statement of the budg-
etary needs of the Office to execute its mission based 
on the good-faith assessment of the Director.’’. 
(f) POWERS AND RESPONSIBILITIES OF THE DIREC-
TOR.—Section 704 of the Office of National Drug Control 
Policy Reauthorization Act of 1998 (21 U.S.C. 1703) is 
amended— 
(1) in subsection (d)(8)—
596 
(A) in subparagraph (D), by striking ‘‘and’’ 
at the end; 
(B) in subparagraph (E)— 
(i) in clause (i)— 
(I) by striking ‘‘Congress, includ-
ing to the Committees on Appropria-
tions of the Senate and the House of 
Representatives, the authorizing com-
mittees for the Office,’’ and inserting 
‘‘the appropriate congressional com-
mittees’’; and 
(II) by striking ‘‘or agencies’’; 
(ii) in clause (ii)— 
(I) by striking ‘‘Congress’’ and in-
serting ‘‘the appropriate congressional 
committees’’; and 
(II) by adding ‘‘and’’ at the end; 
and 
(iii) by adding at the end the fol-
lowing: 
‘‘(iii) funds may only be used for— 
‘‘(I) expansion of demand reduc-
tion activities; 
‘‘(II) interdiction of illicit drugs 
on the high seas, in United States ter-
597 
ritorial waters, and at United States 
ports of entry by officers and employ-
ees of National Drug Control Program 
Agencies and domestic and foreign law 
enforcement officers; 
‘‘(III) accurate assessment and 
monitoring of international drug pro-
duction and interdiction programs and 
policies; 
‘‘(IV) activities to facilitate and 
enhance the sharing of domestic and 
foreign intelligence information among 
National Drug Control Program Agen-
cies related to the production and traf-
ficking of drugs in the United States 
and foreign countries; and 
‘‘(V) research related to any of 
these activities.’’; 
(2) in subsection (e)(2)(A), by striking ‘‘Notwith-
standing any other provision of law’’ and inserting 
‘‘Subject to the availability of appropriations’’; and 
(3) by adding at the end the following: 
‘‘(i) MODEL ACTS PROGRAM.—
598 
‘‘(1) IN GENERAL.—The Director shall provide 
for or shall enter into an agreement with a nonprofit 
organization to— 
‘‘(A) advise States on establishing laws and 
policies to address illicit drug use issues; and 
‘‘(B) revise such model State drug laws and 
draft supplementary model State laws to take 
into consideration changes in illicit drug use 
issues in the State involved. 
‘‘(2) AUTHORIZATION
OF
APPROPRIATIONS.— 
There is authorized to be appropriated to carry out 
this subsection $1,250,000 for each of fiscal years 
2018 through 2023. 
‘‘(j) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI-
NATOR.—The Director shall designate or appoint a United 
States State, Local, and Tribal Affairs Coordinator to per-
form the duties of the Office outlined in this section and 
706 and such other duties as may be determined by the Di-
rector with respect to coordination of drug control efforts 
between agencies and State, local, and Tribal governments. 
The Director shall determine whether the coordinator posi-
tion is a noncareer appointee in the Senior Executive Serv-
ice or a career appointee in a position at level 15 of the 
General Schedule (or equivalent).
599 
‘‘(k) HARM REDUCTION PROGRAMS .—When devel-
oping the national drug control policy, any policy of the 
Director, including policies relating to syringe exchange 
programs for intravenous drug users, shall be based on the 
best available medical and scientific evidence regarding the 
effectiveness of such policy in promoting individual health 
and preventing the spread of infectious disease and the im-
pact of such policy on drug addiction and use. In making 
any policy relating to harm reduction programs, the Direc-
tor shall consult with the National Institutes of Health and 
the National Academy of Sciences.’’. 
(g) ACCOUNTING OF FUNDS EXPENDED.—Section 705 
of the Office of National Drug Control Policy Reauthoriza-
tion Act of 1998 (21 U.S.C. 1704(d)), as amended by section 
8207 is further amended— 
(1) by amending subsection (d) to read as fol-
lows: 
‘‘(d) ACCOUNTING OF FUNDS EXPENDED.— 
‘‘(1) IN GENERAL.—Not later than February 1 of 
each year, in accordance with guidance issued by the 
Director, the head of each National Drug Control Pro-
gram Agency shall submit to the Director a detailed 
accounting of all funds expended by the agency for 
National Drug Control Program activities during the 
previous fiscal year and shall ensure such detailed ac-
600 
counting is authenticated for the previous fiscal year 
by the Inspector General for such agency prior to the 
submission to the Director as frequently as deter-
mined by the Inspector General but not less frequently 
that every 3 years. 
‘‘(2) SUBMISSION TO CONGRESS.—The Director 
shall submit to Congress not later than April 1 of 
each year the information submitted to the Director 
under paragraph (1).’’; and 
(2) by adding at the end the following: 
‘‘(f) TRACKING SYSTEM
FOR FEDERALLY FUNDED 
GRANT PROGRAMS.— 
‘‘(1) ESTABLISHMENT.—The Director, or the 
head of an agency designated by the Director, in co-
ordination with the Secretary of Health and Human 
Services, shall track federally-funded grant programs 
to— 
‘‘(A) ensure the public has electronic access 
to information identifying: 
‘‘(i) all drug control grants and perti-
nent identifying information for each grant; 
‘‘(ii) 
any 
available 
performance 
metrics, evaluations, or other information 
indicating the effectiveness of such pro-
grams;
601 
‘‘(B) facilitate efforts to identify duplica-
tion, overlap, or gaps in funding to provide in-
creased accountability of Federally-funded grants 
for substance use disorder treatment, prevention, 
and enforcement; and 
‘‘(C) identify barriers in the grant applica-
tion process impediments that applicants cur-
rently have in the grant application process with 
applicable agencies. 
‘‘(2) NATIONAL DRUG CONTROL AGENCIES.—The 
head of each National Drug Control Program Agency 
shall provide to the Director a complete list of all 
drug control program grant programs and any other 
relevant information for inclusion in the system de-
veloped under paragraph (1) and annually update 
such list. 
‘‘(3) UPDATING EXISTING SYSTEMS.—The Direc-
tor may meet the requirements of this subsection by 
utilizing, updating, or improving existing Federal in-
formation systems to ensure they meet the require-
ments of this subsection. 
‘‘(4) REPORT.—Not later than 3 years after the 
date of enactment of this subsection, the Comptroller 
General of the United States shall submit to Congress
602 
a report examining implementation of this sub-
section.’’. 
(h) TECHNICAL AND CONFORMING AMENDMENT.—Sec-
tion 1105 of the Office of National Drug Control Policy Re-
authorization Act of 2006 (21 U.S.C. 1701 note) is repealed. 
SEC. 8218. EMERGING THREATS COMMITTEE, PLAN, AND 
MEDIA CAMPAIGN. 
(a) IN GENERAL.—Section 709 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1708) is amended to read as follows: 
‘‘SEC. 709. EMERGING THREATS COMMITTEE, PLAN, AND 
MEDIA CAMPAIGN. 
‘‘(a) EMERGING THREATS COORDINATOR.—The Direc-
tor shall designate or appoint a United States Emerging 
and Continuing Threats Coordinator to perform the duties 
of that position described in this section and such other du-
ties as may be determined by the Director. The Director 
shall determine whether the coordinator position is a non-
career appointee in the Senior Executive Service or a career 
appointee in a position at level 15 of the General Schedule 
(or equivalent). 
‘‘(b) EMERGING THREATS COMMITTEE.— 
‘‘(1) IN GENERAL.—The Emerging Threats Com-
mittee shall—
603 
‘‘(A) monitor evolving and emerging drug 
threats in the United States; 
‘‘(B) identify and discuss evolving and 
emerging drug trends in the United States using 
the criteria required to be established under 
paragraph (6); 
‘‘(C) assist in the formulation of and over-
see implementation of any plan described in sub-
section (d); 
‘‘(D) provide such other advice to the Coor-
dinator and Director concerning strategy and 
policies for emerging drug threats and trends as 
the Committee determines to be appropriate; and 
‘‘(E) disseminate and facilitate the sharing 
with Federal, State, local, and Tribal officials 
and other entities as determined by the Director 
of pertinent information and data relating to— 
‘‘(i) recent trends in drug supply and 
demand; 
‘‘(ii) fatal and nonfatal overdoses; 
‘‘(iii) demand for and availability of 
evidence-based substance use disorder treat-
ment, including the extent of the unmet 
treatment need, and treatment admission 
trends;
604 
‘‘(iv) recent trends in drug interdic-
tion, supply, and demand from State, local, 
and Tribal law enforcement agencies; and 
‘‘(v) other subject matter as determined 
necessary by the Director. 
‘‘(2) CHAIRPERSON.—The Director shall des-
ignate one of the members of the Emerging Threats 
Committee to serve as Chairperson. 
‘‘(3) MEMBERS.—The Director shall appoint 
other members of the Committee, which shall in-
clude— 
‘‘(A) representatives from National Drug 
Control Program Agencies or other agencies; 
‘‘(B) representatives from State, local, and 
Tribal governments; and 
‘‘(C) representatives from other entities as 
designated by the Director. 
‘‘(4) MEETINGS.—The members of the Emerging 
Threats Committee shall meet, in person and not 
through any delegate or representative, not less fre-
quently than once per calendar year, before June 1. 
At the call of the Director or the Chairperson, the 
Emerging Threats Committee may hold additional 
meetings as the members may choose.
605 
‘‘(5) CONTRACT, AGREEMENT, AND OTHER AU-
THORITY.—The Director may award contracts, enter 
into interagency agreements, manage individual 
projects, and conduct other activities in support of the 
identification of emerging drug threats and in sup-
port of the development, implementation, and assess-
ment of any Emerging Threat Response Plan. 
‘‘(6) CRITERIA
TO
IDENTIFY
EMERGING
DRUG 
THREATS.—Not later than 180 days after the date on 
which the Committee first meets, the Committee shall 
develop and recommend to the Director criteria to be 
used to identify an emerging drug threat or the termi-
nation of an emerging drug threat designation based 
on information gathered by the Committee, statistical 
data, and other evidence. 
‘‘(c) DESIGNATION.— 
‘‘(1) IN GENERAL.—The Director, in consultation 
with the Coordinator, the Committee, and the head of 
each National Drug Control Program Agency, may 
designate an emerging drug threat in the United 
States. 
‘‘(2) STANDARDS FOR DESIGNATION.—The Direc-
tor, in consultation with the Coordinator, shall pro-
mulgate and make publicly available standards by 
which a designation under paragraph (1) and the ter-
606 
mination of such designation may be made. In devel-
oping such standards, the Director shall consider the 
recommendations of the committee and other criteria 
the Director considers to be appropriate. 
‘‘(3) PUBLIC STATEMENT REQUIRED.—The Di-
rector shall publish a public written statement on the 
portal of the Office explaining the designation of an 
emerging drug threat or the termination of such des-
ignation and shall notify the appropriate congres-
sional committees of the availability of such statement 
when a designation or termination of such designa-
tion has been made. 
‘‘(d) PLAN.— 
‘‘(1) PUBLIC AVAILABILITY OF PLAN.—Not later 
than 90 days after making a designation under sub-
section (c), the Director shall publish and make pub-
licly available an Emerging Threat Response Plan 
and notify the President and the appropriate congres-
sional committees of such plan’s availability. 
‘‘(2) TIMING.—Concurrently with the annual 
submissions under section 706(g), the Director shall 
update the plan and report on implementation of the 
plan, until the Director issues the public statement re-
quired under subsection (c)(3) to terminate the emerg-
ing drug threat designation.
607 
‘‘(3) CONTENTS OF AN EMERGING THREAT RE-
SPONSE
PLAN.—The Director shall include in the 
plan required under this subsection— 
‘‘(A) a comprehensive strategic assessment 
of the emerging drug threat, including the cur-
rent availability of, demand for, and effectiveness 
of evidence-based prevention, treatment, and en-
forcement programs and efforts to respond to the 
emerging drug threat; 
‘‘(B) comprehensive, research-based, short- 
and long-term, quantifiable goals for addressing 
the emerging drug threat, including for reducing 
the supply of the drug designated as the emerg-
ing drug threat and for expanding the avail-
ability and effectiveness of evidence-based sub-
stance use disorder treatment and prevention 
programs to reduce the demand for the emerging 
drug threat; 
‘‘(C) performance measures pertaining to 
the plan’s goals, including quantifiable and 
measurable objectives and specific targets; 
‘‘(D) the level of funding needed to imple-
ment the plan, including whether funding is 
available to be reprogrammed or transferred to 
support implementation of the plan or whether
608 
additional appropriations are necessary to im-
plement the plan; 
‘‘(E) an implementation strategy for the 
media campaign under subsection (f), including 
goals as described under subparagraph (B) of 
this paragraph and performance measures, objec-
tives, and targets, as described under subpara-
graph (C) of this paragraph; and 
‘‘(F) any other information necessary to in-
form the public of the status, progress, or re-
sponse of an emerging drug threat. 
‘‘(4) IMPLEMENTATION.— 
‘‘(A) IN
GENERAL.—Not later than 120 
days after the date on which a designation is 
made under subsection (c), the Director, in con-
sultation with the President, the appropriate 
congressional committees, and the head of each 
National Drug Control Program Agency, shall 
issue guidance on implementation of the plan de-
scribed in this subsection to the National Drug 
Control Program Agencies and any other rel-
evant agency determined to be necessary by the 
Director. 
‘‘(B) COORDINATOR’S RESPONSIBILITIES.— 
The Coordinator shall—
610 
‘‘(1) IN GENERAL.—The Director shall, to the ex-
tent feasible and appropriate, conduct a national 
anti-drug media campaign (referred to in this subtitle 
as the ‘national media campaign’) in accordance with 
this subsection for the purposes of— 
‘‘(A) preventing substance abuse among peo-
ple in the United States; 
‘‘(B) educating the public about the dangers 
and negative consequences of substance use and 
abuse, including patient and family education 
about the characteristics and hazards of sub-
stance abuse and methods to safeguard against 
substance use, to include the safe disposal of pre-
scription medications; 
‘‘(C) supporting evidence-based prevention 
programs targeting the attitudes, perception, and 
beliefs of persons concerning substance use and 
intentions to initiate or continue such use; 
‘‘(D) encouraging individuals affected by 
substance use disorders to seek treatment and 
providing such individuals with information 
on— 
‘‘(i) how to recognize addiction issues; 
‘‘(ii) what forms of evidence-based 
treatment options are available; and
611 
‘‘(iii) how to access such treatment; 
‘‘(E) combating the stigma of addiction and 
substance use disorders, including the stigma of 
treating such disorders with medication-assisted 
treatment therapies; and 
‘‘(F) informing the public about the dangers 
of any drug identified by the Director as an 
emerging drug threat as appropriate. 
‘‘(2) USE OF FUNDS.— 
‘‘(A) IN GENERAL.—Amounts made avail-
able to carry out this subsection for the national 
media campaign may only be used for the fol-
lowing: 
‘‘(i) The purchase of media time and 
space, including the strategic planning for, 
tracking, and accounting of, such purchases. 
‘‘(ii) Creative and talent costs, con-
sistent with subparagraph (B)(i). 
‘‘(iii) Advertising production costs, 
which may include television, radio, inter-
net, social media, and other commercial 
marketing venues. 
‘‘(iv) Testing and evaluation of adver-
tising.
612 
‘‘(v) Evaluation of the effectiveness of 
the national media campaign. 
‘‘(vi) Costs of contracts to carry out ac-
tivities authorized by this subsection. 
‘‘(vii) Partnerships with professional 
and civic groups, community-based organi-
zations, including faith-based organizations, 
and government organizations related to the 
national media campaign. 
‘‘(viii) Entertainment industry out-
reach, interactive outreach, media projects 
and activities, public information, news 
media outreach, and corporate sponsorship 
and participation. 
‘‘(ix) Operational and management ex-
penses. 
‘‘(B) SPECIFIC REQUIREMENTS.— 
‘‘(i) CREATIVE
SERVICES.—In using 
amounts for creative and talent costs under 
subparagraph (A)(ii), the Director shall use 
creative services donated at no cost to the 
Government wherever feasible and may only 
procure creative services for advertising—
613 
‘‘(I) responding to high-priority 
or emergent campaign needs that can-
not timely be obtained at no cost; or 
‘‘(II) intended to reach a minor-
ity, ethnic, or other special audience 
that cannot reasonably be obtained at 
no cost. 
‘‘(ii) TESTING AND EVALUATION OF AD-
VERTISING.—In using amounts for testing 
and evaluation of advertising under sub-
paragraph (A)(iv), the Director shall test 
all advertisements prior to use in the na-
tional media campaign to ensure that the 
advertisements are effective with the target 
audience and meet industry-accepted stand-
ards. The Director may waive this require-
ment for advertisements using no more than 
10 percent of the purchase of advertising 
time purchased under this subsection in a 
fiscal year and no more than 10 percent of 
the advertising space purchased under this 
subsection in a fiscal year, if the advertise-
ments respond to emergent and time-sen-
sitive campaign needs or the advertisements
614 
will not be widely utilized in the national 
media campaign. 
‘‘(iii) CONSULTATION.—For the plan-
ning of the campaign under paragraph (1), 
the Director may consult with— 
‘‘(I) the head of any appropriate 
National Drug Control Program Agen-
cy; 
‘‘(II) experts on the designated 
drug; 
‘‘(III) State, local, and Tribal 
government officials and relevant agen-
cies; 
‘‘(IV) 
communications 
profes-
sionals; 
‘‘(V) the public; and 
‘‘(VI) appropriate congressional 
committees. 
‘‘(iv) EVALUATION OF EFFECTIVENESS 
OF NATIONAL MEDIA CAMPAIGN.—In using 
amounts for the evaluation of the effective-
ness of the national media campaign under 
subparagraph (A)(v), the Director shall— 
‘‘(I) designate an independent en-
tity to evaluate by April 20 of each
616 
‘‘(3) ADVERTISING.—In carrying out this sub-
section, the Director shall ensure that sufficient funds 
are allocated to meet the stated goals of the national 
media campaign. 
‘‘(4) RESPONSIBILITIES AND FUNCTIONS UNDER 
THE PROGRAM.— 
‘‘(A) IN GENERAL.—The Director shall de-
termine the overall purposes and strategy of the 
national media campaign. 
‘‘(B) DIRECTOR.— 
‘‘(i) IN GENERAL.—The Director shall 
approve— 
‘‘(I) the strategy of the national 
media campaign; 
‘‘(II) all advertising and pro-
motional material used in the national 
media campaign; and 
‘‘(III) the plan for the purchase of 
advertising time and space for the na-
tional media campaign. 
‘‘(ii) IMPLEMENTATION.—The Director 
shall be responsible for implementing a fo-
cused national media campaign to meet the 
purposes set forth in paragraph (1) and 
shall ensure—
617 
‘‘(I) 
information 
disseminated 
through the campaign is accurate and 
scientifically valid; and 
‘‘(II) the campaign is designed 
using strategies demonstrated to be the 
most effective at achieving the goals 
and requirements of paragraph (1), 
which may include— 
‘‘(aa) a media campaign, as 
described in paragraph (2); 
‘‘(bb) local, regional, or pop-
ulation specific messaging; 
‘‘(cc) 
the 
development 
of 
websites to publicize and dissemi-
nate information; 
‘‘(dd) 
conducting 
outreach 
and providing educational re-
sources for parents; 
‘‘(ee) collaborating with law 
enforcement agencies; and 
‘‘(ff) providing support for 
school-based public health edu-
cation classes to improve teen 
knowledge about the effects of sub-
stance use.
618 
‘‘(5) PROHIBITIONS.—None of the amounts made 
available under paragraph (2) may be obligated or 
expended for any of the following: 
‘‘(A) To supplant current anti-drug commu-
nity-based coalitions. 
‘‘(B) To supplant pro bono public service 
time donated by national and local broadcasting 
networks for other public service campaigns. 
‘‘(C) For partisan political purposes, or to 
express advocacy in support of or to defeat any 
clearly identified candidate, clearly identified 
ballot initiative, or clearly identified legislative 
or regulatory proposal. 
‘‘(D) To fund advertising that features any 
elected officials, persons seeking elected office, 
cabinet level officials, or other Federal officials 
employed pursuant to section 213 of Schedule C 
of title 5, Code of Federal Regulations. 
‘‘(E) To fund advertising that does not con-
tain a primary message intended to reduce or 
prevent substance use. 
‘‘(F) To fund advertising containing a pri-
mary message intended to promote support for 
the national media campaign or private sector 
contributions to the national media campaign.
619 
‘‘(6) MATCHING REQUIREMENT.— 
‘‘(A) IN GENERAL.—Amounts made avail-
able under paragraph (2) for media time and 
space shall be matched by an equal amount of 
non-Federal funds for the national media cam-
paign, or be matched with in-kind contributions 
of the same value. 
‘‘(B) NO-COST MATCH ADVERTISING DIRECT 
RELATIONSHIP
REQUIREMENT.—The 
Director 
shall ensure that not less than 85 percent of no- 
cost match advertising directly relates to sub-
stance abuse prevention consistent with the spe-
cific purposes of the national media campaign. 
‘‘(C) NO-COST MATCH ADVERTISING NOT DI-
RECTLY
RELATED.—The Director shall ensure 
that no-cost match advertising that does not di-
rectly relate to substance abuse prevention con-
sistent with the purposes of the national media 
campaign includes a clear anti-drug message. 
Such message is not required to be the primary 
message of the match advertising. 
‘‘(7) FINANCIAL
AND
PERFORMANCE
ACCOUNT-
ABILITY.—The Director shall cause to be performed—
620 
‘‘(A) audits and reviews of costs of the na-
tional media campaign pursuant to section 4706 
of title 41, United States Code; and 
‘‘(B) an audit to determine whether the 
costs of the national media campaign are allow-
able under chapter 43 of title 41, United States 
Code. 
‘‘(8) REPORT TO CONGRESS.—The Director shall 
submit on an annual basis a report to Congress that 
describes— 
‘‘(A) the strategy of the national media 
campaign and whether specific objectives of the 
national media campaign were accomplished; 
‘‘(B) steps taken to ensure that the national 
media campaign operates in an effective and ef-
ficient manner consistent with the overall strat-
egy and focus of the national media campaign; 
‘‘(C) plans to purchase advertising time 
and space; 
‘‘(D) policies and practices implemented to 
ensure that Federal funds are used responsibly to 
purchase advertising time and space and elimi-
nate the potential for waste, fraud, and abuse;
621 
‘‘(E) all contracts entered into with a cor-
poration, partnership, or individual working on 
behalf of the national media campaign; 
‘‘(F) the results of any financial audit of 
the national media campaign; 
‘‘(G) a description of any evidence used to 
develop the national media campaign; 
‘‘(H) specific policies and steps imple-
mented to ensure compliance with this section; 
‘‘(I) a detailed accounting of the amount of 
funds obligated during the previous fiscal year 
for carrying out the national media campaign, 
including each recipient of funds, the purpose of 
each expenditure, the amount of each expendi-
ture, any available outcome information, and 
any other information necessary to provide a 
complete accounting of the funds expended; and 
‘‘(J) a review and evaluation of the effec-
tiveness of the national media campaign strategy 
for the past year. 
‘‘(9) REQUIRED
NOTICE
FOR
COMMUNICATION 
FROM THE OFFICE.—Any communication, including 
an advertisement, paid for or otherwise disseminated 
by the Office directly or through a contract awarded 
by the Office shall include a prominent notice inform-
622 
ing the audience that the communication was paid 
for by the Office. 
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Office to carry out this 
section, $25,000,000 for each of fiscal years 2018 through 
2023.’’. 
(b) TECHNICAL AND CONFORMING AMENDMENT.—Sub-
section (a) of section 203 of the Office of National Drug 
Control Policy Reauthorization Act of 2006 (21 U.S.C. 
1708a) is repealed. 
SEC. 8219. DRUG INTERDICTION. 
(a) REPEAL.—This first section 711 of the Office of 
National Drug Control Policy Reauthorization Act of 1998 
(21 U.S.C. 1710) is repealed. 
(b) AMENDMENTS.—Section 711 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1710), as added by Public Law 109–469 (120 Stat. 
3507), is amended— 
(1) in subsection (a)— 
(A) in paragraph (1)— 
(i) by striking ‘‘The United’’ and in-
serting ‘‘The Director shall designate or ap-
point an appointee in the Senior Executive 
Service or an appointee in a position at
623 
level 15 of the General Schedule (or equiva-
lent) as the United’’; and 
(ii) by striking ‘‘shall’’ and inserting 
‘‘to’’; 
(B) in paragraph (2)(B)— 
(i) by striking ‘‘March 1’’ and insert-
ing ‘‘September 1’’; and 
(ii) by striking ‘‘paragraph (3)’’ and 
inserting ‘‘paragraph (4)’’; 
(C) in paragraph (3)— 
(i) by striking ‘‘also, at his discre-
tion,’’; and 
(ii) by striking ‘‘the Office of Supply 
Reduction for that purpose’’ and inserting 
‘‘assist in carrying out such responsibil-
ities’’; and 
(D) in paragraph (4)— 
(i) in subparagraph (B), by striking 
‘‘The United’’ and inserting ‘‘Before sub-
mission of the National Drug Control Strat-
egy or annual assessment required under 
section 706, as applicable, the United’’; 
(ii) by striking subparagraphs (C) and 
(E);
624 
(iii) by redesignating subparagraph 
(D) as subparagraph (C); 
(iv) in subparagraph (C), as so redes-
ignated— 
(I) in the matter preceding clause 
(i)— 
(aa) by striking ‘‘March 1’’ 
and inserting ‘‘September 1’’; 
(bb) by inserting ‘‘the Direc-
tor, acting through’’ before ‘‘the 
United States’’; 
(cc) by inserting a comma 
after ‘‘Coordinator’’; 
(dd) by striking ‘‘a report on 
behalf of the Director’’; and 
(ee) by striking ‘‘, which 
shall include’’ and inserting ‘‘a 
report that’’; 
(II) by redesignating clauses (i), 
(ii), and (iii) as subclauses (I), (II), 
and (III), and adjusting the margins 
accordingly; 
(III) by inserting before subclause 
(I), as so redesignated, the following: 
‘‘(i) includes—’’;
625 
(IV) in clause (i), as so redesig-
nated— 
(aa) in subclause (I), as so 
redesignated, by inserting ‘‘, in-
cluding information about how 
each National Drug Control Pro-
gram agency conducting drug 
interdiction activities is engaging 
with relevant international part-
ners’’ after ‘‘Plan’’; 
(bb) in subclause (II), as so 
redesignated, by striking ‘‘, as 
well as’’ and inserting ‘‘and’’; 
(cc) in subclause III, as so 
redesignated— 
(AA) by striking ‘‘, as 
well 
as’’ 
and 
inserting 
‘‘and’’; and 
(BB) by striking the pe-
riod at the end and inserting 
‘‘; and’’; and 
(V) by adding at the end the fol-
lowing: 
‘‘(ii) may include recommendations for 
changes to existing agency authorities or
626 
laws governing interagency relationships.’’; 
and 
(v) by adding at the end the following: 
‘‘(D) CLASSIFIED ANNEX.—Each report re-
quired to be submitted under subparagraph (C) 
shall be in unclassified form, but may include a 
classified annex.’’; 
(2) in subsection (b)— 
(A) in paragraph (1)(B), by inserting ‘‘and 
how to strengthen international partnerships to 
better achieve the goals of that plan’’ after ‘‘that 
plan’’; 
(B) in paragraph (2)— 
(i) in the paragraph heading, by strik-
ing ‘‘CHAIRMAN’’ and inserting ‘‘CHAIR-
PERSON’’; and 
(ii) by striking ‘‘chairman’’ and in-
serting ‘‘Chairperson’’; 
(C) in paragraph (3)— 
(i) by striking ‘‘prior to March 1’’ and 
inserting ‘‘before June 1’’; 
(ii) by striking ‘‘either’’ each place it 
appears; 
(iii) by striking ‘‘current chairman’’ 
and inserting ‘‘Chairperson’’; and
627 
(iv) by striking ‘‘they’’ and inserting 
‘‘the members’’; and 
(D) in paragraph (4)— 
(i) by striking ‘‘chairman’’ each place 
it appears and inserting ‘‘Chairperson’’; 
(ii) in the first sentence, by striking ‘‘a 
report’’; 
(iii) by inserting ‘‘a report’’ after 
‘‘committees’’; and 
(iv) by striking the second sentence and 
inserting the following: ‘‘The report required 
under this paragraph shall be in unclassi-
fied form, but may include a classified 
annex.’’; and 
(3) by adding at the end the following: 
‘‘(c) INTERNATIONAL COORDINATION.—The Director 
may facilitate international drug control coordination ef-
forts.’’. 
SEC. 8220. GAO AUDIT. 
Not later than 4 years after the date of enactment of 
this Act, and every 4 years thereafter, the Comptroller Gen-
eral of the United States shall— 
(1) conduct an audit relating to the programs 
and operations of— 
(A) the Office; and
628 
(B) certain programs within the Office, in-
cluding— 
(i) the High Intensity Drug Traf-
ficking Areas Program; 
(ii) the Drug-Free Communities Pro-
gram; and 
(iii) the campaign under section 709(f) 
of the Office of National Drug Control Pol-
icy Reauthorization Act of 1998 (21 U.S.C. 
1708(f)); and 
(2) submit to the Director and the appropriate 
congressional committees a report containing an eval-
uation of and recommendations on the— 
(A) policies and activities of the programs 
and operations subject to the audit; 
(B) economy, efficiency, and effectiveness in 
the administration of the reviewed programs and 
operations; and 
(C) policy or management changes needed 
to prevent and detect fraud and abuse in such 
programs and operations. 
SEC. 8221. NATIONAL DRUG CONTROL STRATEGY. 
(a) IN GENERAL.—Section 706 of the Office of Na-
tional Drug Control Policy Reauthorization Act of 1998 (21 
U.S.C. 1705) is amended to read as follows:
629 
‘‘SEC. 706. NATIONAL DRUG CONTROL STRATEGY. 
‘‘(a) IN GENERAL.— 
‘‘(1) STATEMENT
OF
DRUG
POLICY
PRIOR-
ITIES.—The Director shall release a statement of drug 
control policy priorities in the calendar year of a 
Presidential inauguration following the inauguration, 
but not later than April 1. 
‘‘(2) NATIONAL DRUG CONTROL STRATEGY SUB-
MITTED BY THE PRESIDENT.—Not later than the first 
Monday in February following the year in which the 
term of the President commences, and every 2 years 
thereafter, the President shall submit to Congress a 
National Drug Control Strategy. 
‘‘(b) DEVELOPMENT OF THE NATIONAL DRUG CON-
TROL STRATEGY.— 
‘‘(1) PROMULGATION.—The Director shall pro-
mulgate the National Drug Control Strategy, which 
shall set forth a comprehensive plan to reduce illicit 
drug use and the consequences of such illicit drug use 
in the United States by limiting the availability of 
and reducing the demand for illegal drugs and pro-
moting prevention, early intervention, treatment, and 
recovery support for individuals with substance use 
disorders. 
‘‘(2) STATE AND LOCAL COMMITMENT.—The Di-
rector shall seek the support and commitment of
630 
State, local, and Tribal officials in the formulation 
and implementation of the National Drug Control 
Strategy. 
‘‘(3) STRATEGY BASED ON EVIDENCE.—The Di-
rector shall ensure the National Drug Control Strat-
egy is based on the best available evidence regarding 
the policies that are most effective in reducing the de-
mand for and supply of illegal drugs. 
‘‘(4) PROCESS FOR DEVELOPMENT AND SUBMIS-
SION OF NATIONAL DRUG CONTROL STRATEGY.—In 
developing and effectively implementing the National 
Drug Control Strategy, the Director— 
‘‘(A) shall consult with— 
‘‘(i) the heads of the National Drug 
Control Program Agencies; 
‘‘(ii) each Coordinator listed in section 
704; 
‘‘(iii) the Interdiction Committee and 
the Emerging Threats Committee; 
‘‘(iv) the appropriate congressional 
committees and any other committee of ju-
risdiction; 
‘‘(v) State, local, and Tribal officials; 
‘‘(vi) private citizens and organiza-
tions, including community and faith-based
631 
organizations, with experience and expertise 
in demand reduction; 
‘‘(vii) private citizens and organiza-
tions with experience and expertise in sup-
ply reduction; and 
‘‘(viii) appropriate representatives of 
foreign governments; and 
‘‘(B) in satisfying the requirements of sub-
paragraph (A), shall ensure, to the maximum ex-
tent possible, that State, local, and Tribal offi-
cials and relevant private organizations commit 
to support and take steps to achieve the goals 
and objectives of the National Drug Control 
Strategy. 
‘‘(c) CONTENTS OF THE NATIONAL DRUG CONTROL 
STRATEGY.— 
‘‘(1) IN GENERAL.—The National Drug Control 
Strategy submitted under subsection (a)(2) shall in-
clude the following: 
‘‘(A) A mission statement detailing the 
major functions of the National Drug Control 
Program. 
‘‘(B) Comprehensive, research-based, long- 
range, quantifiable goals for reducing illicit drug
632 
use, and the consequences of illicit drug use in 
the United States. 
‘‘(C) Annual quantifiable and measurable 
objectives and specific targets to accomplish long- 
term quantifiable goals that the Director deter-
mines may be achieved during each year begin-
ning on the date on which the National Drug 
Control Strategy is submitted. 
‘‘(D) A 5-year projection for the National 
Drug Control Program and budget priorities. 
‘‘(E) A review of international, State, local, 
and private sector drug control activities to en-
sure that the United States pursues coordinated 
and effective drug control at all levels of govern-
ment. 
‘‘(F) A description of how each goal estab-
lished under subparagraph (B) will be achieved, 
including for each goal— 
‘‘(i) a list of each relevant National 
Drug Control Program Agency and each 
such agency’s related programs, activities, 
and available assets and the role of each 
such program, activity, and asset in achiev-
ing such goal;
633 
‘‘(ii) a list of relevant stakeholders and 
each such stakeholder’s role in achieving 
such goal; 
‘‘(iii) an estimate of Federal funding 
and other resources needed to achieve such 
goal; 
‘‘(iv) a list of each existing or new co-
ordinating mechanism needed to achieve 
such goal; and 
‘‘(v) a description of the Office’s role in 
facilitating the achievement of such goal. 
‘‘(G) For each year covered by the Strategy, 
a performance evaluation plan for each goal es-
tablished under subparagraph (B) for each Na-
tional Drug Control Program Agency, includ-
ing— 
‘‘(i) specific performance measures for 
each National Drug Control Program Agen-
cy; 
‘‘(ii) annual and, to the extent prac-
ticable, quarterly objectives and targets for 
each performance measure; and 
‘‘(iii) an estimate of Federal funding 
and other resources needed to achieve each 
performance objective and target.
636 
‘‘(iv) a list of any challenges to devel-
oping evidence to support policymaking, in-
cluding any barriers to accessing, collecting, 
or using relevant data; 
‘‘(v) a description of the steps the Di-
rector and the head of each National Drug 
Control Program Agency will take to effec-
tuate the plan; and 
‘‘(vi) any other relevant information as 
determined by the Director. 
‘‘(N) A plan to expand treatment of sub-
stance use disorders, which shall— 
‘‘(i) identify unmet needs for treatment 
for substance use disorders and a strategy 
for closing the gap between available and 
needed treatment; 
‘‘(ii) describe the specific roles and re-
sponsibilities of the relevant National Drug 
Control Programs for implementing the 
plan; 
‘‘(iii) identify the specific resources re-
quired to enable the relevant National Drug 
Control Agencies to implement that strat-
egy; and
637 
‘‘(iv) identify the resources, including 
private sources, required to eliminate the 
unmet need for evidence-based substance use 
disorder treatment. 
‘‘(2) CONSULTATION.—In developing the plan re-
quired under paragraph (1), the Director shall con-
sult with the following: 
‘‘(A) The public. 
‘‘(B) Any evaluation or analysis units and 
personnel of the Office. 
‘‘(C) Office officials responsible for imple-
menting privacy policy. 
‘‘(D) Office officials responsible for data 
governance. 
‘‘(E) The appropriate congressional com-
mittees. 
‘‘(F) Any other individual or entity as de-
termined by the Director. 
‘‘(3) ADDITIONAL STRATEGIES.— 
‘‘(A) IN GENERAL.—The Director shall in-
clude in the National Drug Control Strategy the 
additional strategies described under this para-
graph and shall comply with the following: 
‘‘(i) Provide a copy of the additional 
strategies to the appropriate congressional
638 
committees and to the Committee on Armed 
Services and the Committee on Homeland 
Security of the House of Representatives, 
and the Committee on Homeland Security 
and Governmental Affairs and the Com-
mittee on Armed Services of the Senate. 
‘‘(ii) Issue the additional strategies in 
consultation with the head of each relevant 
National Drug Control Program Agency, 
any relevant official of a State, local, or 
Tribal government, and the government of 
other relevant countries. 
‘‘(iii) Not change any existing agency 
authority or construe any strategy described 
under this paragraph to amend or modify 
any law governing interagency relationship 
but may include recommendations about 
changes to such authority or law. 
‘‘(iv) Present separately from the rest 
of any strategy described under this para-
graph any information classified under cri-
teria established by an Executive order, or 
whose public disclosure, as determined by 
the Director or the head of any relevant Na-
tional Drug Control Program Agency,
639 
would be detrimental to the law enforcement 
or national security activities of any Fed-
eral, State, local, or Tribal agency. 
‘‘(B) REQUIREMENT FOR SOUTHWEST BOR-
DER COUNTERNARCOTICS STRATEGY.— 
‘‘(i) PURPOSES.—The Southwest Bor-
der Counternarcotics Strategy shall— 
‘‘(I) set forth the Government’s 
strategy for preventing the illegal traf-
ficking of drugs across the inter-
national border between the United 
States and Mexico, including through 
ports of entry and between ports of 
entry on that border; 
‘‘(II) state the specific roles and 
responsibilities of the relevant National 
Drug Control Program Agencies for 
implementing that strategy; and 
‘‘(III) identify the specific re-
sources required to enable the relevant 
National Drug Control Program Agen-
cies to implement that strategy. 
‘‘(ii) SPECIFIC CONTENT RELATED TO 
DRUG
TUNNELS
BETWEEN
THE
UNITED 
STATES AND MEXICO.—The Southwest Bor-
640 
der Counternarcotics Strategy shall in-
clude— 
‘‘(I) a strategy to end the con-
struction and use of tunnels and sub-
terranean passages that cross the inter-
national border between the United 
States and Mexico for the purpose of il-
legal trafficking of drugs across such 
border; and 
‘‘(II) recommendations for crimi-
nal penalties for persons who construct 
or use such a tunnel or subterranean 
passage for such a purpose. 
‘‘(C) REQUIREMENT FOR NORTHERN BOR-
DER COUNTERNARCOTICS STRATEGY.— 
‘‘(i) PURPOSES.—The Northern Border 
Counternarcotics Strategy shall— 
‘‘(I) set forth the strategy of the 
Federal Government for preventing the 
illegal trafficking of drugs across the 
international 
border 
between 
the 
United States and Canada, including 
through ports of entry and between 
ports of entry on the border;
641 
‘‘(II) state the specific roles and 
responsibilities of each relevant Na-
tional Drug Control Program Agency 
for implementing the strategy; 
‘‘(III) identify the specific re-
sources required to enable the relevant 
National Drug Control Program Agen-
cies to implement the strategy; 
‘‘(IV) be designed to promote, and 
not hinder, legitimate trade and travel; 
and 
‘‘(V) reflect the unique nature of 
small communities along the inter-
national border between the United 
States and Canada, ongoing coopera-
tion and coordination with Canadian 
law, enforcement authorities, and vari-
ations in the volumes of vehicles and 
pedestrians crossing through ports of 
entry along the international border 
between the United States and Canada. 
‘‘(ii) SPECIFIC CONTENT RELATED TO 
CROSS-BORDER
INDIAN
RESERVATIONS.— 
The 
Northern 
Border 
Counternarcotics 
Strategy shall include—
642 
‘‘(I) a strategy to end the illegal 
trafficking of drugs to or through In-
dian reservations on or near the inter-
national border between the United 
States and Canada; and 
‘‘(II) recommendations for addi-
tional assistance, if any, needed by 
Tribal law enforcement agencies relat-
ing to the strategy, including an eval-
uation of Federal technical and finan-
cial assistance, infrastructure capacity 
building, and interoperability defi-
ciencies. 
‘‘(4) CLASSIFIED
INFORMATION.—Any contents 
of the National Drug Control Strategy that involve 
information properly classified under criteria estab-
lished by an Executive order shall be presented to 
Congress separately from the rest of the National 
Drug Control Strategy. 
‘‘(5) SELECTION OF DATA AND INFORMATION.— 
In selecting data and information for inclusion in the 
Strategy, the Director shall ensure— 
‘‘(A) the inclusion of data and information 
that will permit analysis of current trends 
against previously compiled data and informa-
643 
tion where the Director believes such analysis en-
hances long-term assessment of the National 
Drug Control Strategy; and 
‘‘(B) the inclusion of data and information 
to permit a standardized and uniform assess-
ment of the effectiveness of drug treatment pro-
grams in the United States. 
‘‘(d) SUBMISSION OF REVISED STRATEGY.—The Presi-
dent may submit to Congress a revised National Drug Con-
trol Strategy that meets the requirements of this section— 
‘‘(1) at any time, upon a determination of the 
President, in consultation with the Director, that the 
National Drug Control Strategy in effect is not suffi-
ciently effective; or 
‘‘(2) if a new President or Director takes office. 
‘‘(e) FAILURE OF DIRECTOR TO SUBMIT NATIONAL 
DRUG CONTROL STRATEGY.—If the Director does not sub-
mit a National Drug Control Strategy to Congress in ac-
cordance with subsection (a)(2), not later than five days 
after the first Monday in February following the year in 
which the term of the President commences, the Director 
shall send a notification to the appropriate congressional 
committees— 
‘‘(1) explaining why the Strategy was not sub-
mitted; and
644 
‘‘(2) specifying the date by which the Strategy 
will be submitted. 
‘‘(f) DRUG CONTROL DATA DASHBOARD.— 
‘‘(1) IN
GENERAL.—The Director shall collect 
and disseminate, as appropriate, such information as 
the Director determines is appropriate, but not less 
than the information described in this subsection. The 
data shall be publicly available in a machine-readable 
format on the online portal of the Office, and to the 
extent practicable on the Drug Control Data Dash-
board. 
‘‘(2) ESTABLISHMENT.—The Director shall pub-
lish to the online portal of the office in a machine- 
readable, sortable, and searchable format, or to the ex-
tent practicable, establish and maintain a data dash-
board on the online portal of the Office to be known 
as the ‘Drug Control Data Dashboard’. To the extent 
practicable, when establishing the Drug Control Dash-
board, the Director shall ensure the user interface of 
the dashboard is constructed with modern design 
standards. To the extent practicable, the data made 
available on the dashboard shall be publicly available 
in a machine-readable format and searchable by year, 
agency, drug, and location.
645 
‘‘(3) DATA.—The data included in the Drug 
Control Data Dashboard shall be updated quarterly to 
the extent practicable, but not less frequently than an-
nually and shall include, at a minimum, the fol-
lowing: 
‘‘(A) For each substance identified by the 
Director as having a significant impact on the 
prevalence of illicit drug use— 
‘‘(i) data sufficient to show the quan-
tities of such substance available in the 
United States, including— 
‘‘(I) the total amount seized and 
disrupted in the calendar year and 
each of the previous 3 calendar years, 
including to the extent practicable the 
amount seized by State, local, and 
Tribal governments; 
‘‘(II) the known and estimated 
flows into the United States from all 
sources in the calendar year and each 
of the previous 3 calendar years; 
‘‘(III) the total amount of known 
flows that could not be interdicted or 
disrupted in the calendar year and 
each of the previous 3 calendar years;
646 
‘‘(IV) the known and estimated 
levels of domestic production in the 
calendar year and each of the previous 
three calendar years, including the lev-
els of domestic production if the drug 
is a prescription drug, as determined 
under the Federal Food, Drug, and 
Cosmetic Act, for which a listing is in 
effect under section 202 of the Con-
trolled Substances Act (21 U.S.C. 812); 
‘‘(V) the average street price for 
the calendar year and the highest 
known street price during the pre-
ceding 10-year period; and 
‘‘(VI) to the extent practicable, re-
lated prosecutions by State, local, and 
Tribal governments; 
‘‘(ii) data sufficient to show the fre-
quency of use of such substance, including— 
‘‘(I) use of such substance in the 
workplace and productivity lost by 
such use; 
‘‘(II) use of such substance by 
arrestees, probationers, and parolees;
647 
‘‘(III) crime and criminal activ-
ity related to such substance; 
‘‘(IV) to the extent practicable, re-
lated prosecutions by State, local, and 
Tribal governments; 
‘‘(B) For the calendar year and each of the 
previous three years data sufficient to show, 
disaggregated by State and, to the extent feasible, 
by region within a State, county, or city, the fol-
lowing: 
‘‘(i) The number of fatal and non-fatal 
overdoses caused by each drug identified 
under subparagraph (A)(i). 
‘‘(ii) The prevalence of substance use 
disorders. 
‘‘(iii) The number of individuals who 
have received substance use disorder treat-
ment, including medication assisted treat-
ment, for a substance use disorder, includ-
ing treatment provided through publicly-fi-
nanced health care programs. 
‘‘(iv) The extent of the unmet need for 
substance use disorder treatment, including 
the unmet need for medication-assisted 
treatment.
651 
(A) by striking paragraphs (13) and (17); 
and 
(B) in paragraph (14)(A), by striking 
‘‘paragraph 
(13)’’ 
and 
inserting 
‘‘section 
706(g)(2)’’. 
(2) The Office of National Drug Control Policy 
Reauthorization Act of 2006 (Public Law 109–469; 
120 Stat. 3502) is amended by striking sections 1110 
and 1110A. 
SEC. 8222. TECHNICAL AND CONFORMING AMENDMENTS TO 
THE OFFICE OF NATIONAL DRUG CONTROL 
POLICY REAUTHORIZATION ACT OF 1998. 
The Office of National Drug Control Policy Reauthor-
ization Act of 1998 (21 U.S.C. 1701 et seq.) is amended— 
(1) by striking section 703(b) (21 U.S.C. 
1702(b)); 
(2) in section 704 (21 U.S.C. 1703)— 
(A) in subsection (c)— 
(i) in paragraph (3)(C)— 
(I) in the matter before clause (i), 
by inserting ‘‘requests a level of fund-
ing that will not enable achievement of 
the goals of the National Drug Control 
Strategy, including’’ after ‘‘request 
that’’;
652 
(II) in clause (iii)— 
(aa) by striking ‘‘drug treat-
ment’’ and inserting ‘‘substance 
use disorder prevention and treat-
ment’’; and 
(bb) by striking the semicolon 
at the end and inserting ‘‘; and’’; 
(III) by striking clauses (iv), (vi), 
and (vii); 
(IV) by redesignating clause (v) 
as clause (iv); and 
(V) in clause (iv), as so redesig-
nated, by striking the semicolon and 
inserting a period; 
(ii) in paragraph (4)(A), by striking 
‘‘$1,000,000’’ and inserting ‘‘$5,000,000 or 
10 percent of a specific program or ac-
count’’; and 
(B) in subsection (f)— 
(i) by striking the first paragraph (5); 
and 
(ii) by striking the second paragraph 
(4); and 
(3) by striking section 708 (21 U.S.C. 1707).
653 
Subtitle L—Budgetary Effects 
SEC. 8231. BUDGETARY EFFECT. 
(a) IN GENERAL.—The budgetary effects of this Act 
shall not be entered on either PAYGO scorecard maintained 
pursuant to section 4(d) of the Statutory Pay-As-You-Go 
Act of 2010 (2 U.S.C. 933(d)). 
(b) SENATE PAYGO SCORECARDS.—The budgetary ef-
fects of this Act shall not be entered on any PAYGO score-
card maintained for purposes of section 4106 of H. Con. 
Res. 71 (115th Congress). 
Attest: 
Clerk.
115TH CONGRESS 
2D SESSION 
H.R. 6 
HOUSE AMENDMENT TO 
SENATE AMENDMENT